The Evolution of Lupus Nephritis Treatment; from Conventional to Targeted and Biologics Therapy

Warot Piriyasanguanpong; Siriporn Juthong; Duangkamol Aiewruengsurat; Porntip Intapiboon

doi:10.31584/jhsmr.20241125

The Evolution of Lupus Nephritis Treatment; from Conventional to Targeted and Biologics Therapy

Warot Piriyasanguanpong, Siriporn Juthong, Duangkamol Aiewruengsurat, Porntip Intapiboon

Abstract

Lupus nephritis (LN) is a common and severe organ manifestation in patients with systemic lupus erythematosus (SLE). LN can present alone or with accompanying extra-renal symptoms. The prevalence and severity vary depending on ethnicity, genetics, and environmental exposure. However, the presence of LN in SLE is a surrogate indicator of disease severity, frequent relapse, increased chronic kidney disease (CKD), and mortality risks. The current conventional standard treatments for LN include corticosteroids, immunosuppressive drugs, and antimalarial drugs. Despite an optimal standard treatment regimen, the outcomes of renal remission, decreased CKD risk, and quality of life are unsatisfactory. In addition, corticosteroid and immunosuppressive drug toxicity are of primary concern. Thus, two dozen promising biological and targeted drugs are being studied in the LN treatment pipeline to improve renal outcomes and mitigate the side effects of conventional therapy. This article aims to review the pathogenesis of LN, summarise the current conventional strategy, and highlight the candidate novel drugs in LN included in Phase II and III clinical trials. These biologics, or targeted therapies, are hoped to facilitate the advancement of the LN treatment paradigm in the era of precision medicine.

Keywords

biologic therapy; lupus nephritis; systemic lupus erythematosus; targeted therapy

Full Text:

PDF

References

Kamen DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin North Am 2014; 40:401-12. doi: 10.1016/j.rdc.2014.05.003.

Mejía-Vilet JM, Ayoub I. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Front Med (Lausanne) 2021;8:622225. doi: 10.3389/fmed.2021.622225.

Austin HA, 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9. doi: 10.1056/NEJM198603063141004.

Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31. doi: 10.1002/art.10461.

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12. doi: 10.1681/asn.2008101028.

Rovin BH, Solomons N, Pendergraft WF, 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019;95:219-31. doi: 10.1016/j.kint.2018.08.025.

Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26. doi: 10.7326/m14-1030.

Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in Lupus Nephritis. N Engl J Med 2020;383:1117-28. doi: 10.1056/NEJMoa2001180.

Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070-80. doi: 10.1016/s0140-6736(21)00578-x.

Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80. doi: 10.1056/NEJMoa031855.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for Lupus Nephritis. New Engl J Med2011;365:1886-95. doi: 10.1056/NEJMoa1014460.

Zhang H, Liu Z, Zhou M, Liu Z, Chen J, Xing C, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 2017;28:3671-8. doi: 10.1681/asn.2017030263.

Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 2022;101:403-13. doi: 10.1016/j.kint.2021.08.027.

Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 aurora 2 clinical trial. Arthritis Rheumatol 2024;76:59-67. doi: 10.1002/art.42657.

Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65: 521-30. doi: 10.1111/j.1523-1755.2004.00443.x.

Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018;93:789-96. doi: 10.1016/j.kint.2017.11.023.

Antonis F, Myrto K, Jeanette A, Martin A, Laurent A, Sang-Cheol B, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2023:2023-224762. doi: 10.1136/ard-2023-224762.

Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713-23. doi: 10.1136/annrheumdis-2020-216924.

Rovin BH, Ayoub IM, Chan TM, Liu Z-H, Mejía-Vilet JM, Floege J. kdigo 2024 clinical practice guideline for the management of lupus nephritis. Kidney International 2024;105:S1-69. doi: 10.1016/j.kint.2023.09.002.

Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011;63:1681-8. doi: 10.1002/art.30293.

Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, et al. Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis Rheumatol 2024;76:59-67. doi: 10.1002/art.42657.

Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Eng J Med 2020;383:1117-28. doi: 10.1056/NEJMoa2001180.

Anders H-J, Furie R, Malvar A, Zhao M-H, Hiromura K, Weinmann-Menke J, et al. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 bliss-ln trial. Nephrol Dial Transplant 2023;38:2733-42. doi: 10.1093/ndt/gfad167.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:1016-27. doi: 10.1002/art.40049.

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26. doi: 10.1002/art.34359.

Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6. doi: 10.1136/annrheumdis-2012-202844.

Zhong Z, Li H, Zhong H and Zhou T. Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther 2019;13: 845-56. doi: 10.2147/dddt.S195113.

Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022;81:100-7. 20211006. doi: 10.1136/annrheumdis-2021-220920.

Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015;74:2006-15. doi: 10.1136/annrheumdis-2013-205067.

Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14:R33. doi: 10.1186/ar3738.

Wu D LJ, Xu D, et al. Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study [Abstract] number: Arthritis Rheumatol 2022;74(Suppl 9).

Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nature Medicine 2023;29:2041-7. doi: 10.1038/s41591-023-02479-1.

Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 2023;401:1001-10. doi: 10.1016/s0140-673602607-1.

Petri M, Bruce IN, Dörner T, Tanaka Y, Morand EF, Kalunian KC, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 2023;401:1011-19. doi: 10.1016/s0140-6736(22)02546-6.

Hassanien M, Moshrif A and Hetta H. OP0053 efficacy and safety of baricitinib in patients with active lupus nephritis: a double-blind, randomized, placebo-controlled phase 3 trial. Ann Rheum Dis 2023;82:34-5. doi: 10.1136/annrheumdis-2023-eular.895.

Ji L, Xie W, Zhang Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum 2020;50:1073-80. doi: 10.1016/j.semarthrit.2020.07.006.

Yap DYH, Tang C, Chan GCW, Kwan LPY, Ma MKM, Mok MMY, et al. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. J Rheumatol 2018;45:1663-70. doi: 10.3899/jrheum.180507.

Saxena A, Parikh S, Hua S, Leff R, Park E, Henig N. POS1128 zetomipzomib (kzr-616) treatment results in clinically meaningful renal responses in patients with lupus nephritis. Ann Rheum Dis 2023;82:891-2. doi: 10.1136/annrheumdis-2023-eular.2317.

Shao M, He J, Zhang R, Zhang X, Yang Y, Li C, et al. Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus. J Interferon Cytokine Res 2019; 39:117-24. doi: 10.1089/jir.2018.0016.

Zhang X, Feng R, Shao M, Wang Y, Sun X and He J. Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis. Rheumatol Ther 2021;8:1905-14. doi: 10.1007/s40744-021-00381-1.

Jing H, Ruijun Z, Miao S, Xiaozhen Z, Miao M, Jiali C, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2020;79:141. doi: 10.1136/annrheumdis-2019-215396.

Jens YH, Patrice C, Michelle R, Fabien P, Hang Phuong P, Joel G, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis 2022;81:1685. doi: 10.1136/ard-2022-222501.

David J, Brad R, Eduardo FM, Richard AF, Frederic AH, Teodora T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022;81:496. doi: 10.1136/annrheumdis-2021-221478.

Jayne D, Rovin B, Mysler E, Furie R, Houssiau F, Trasieva T, et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med 2023; 10. doi: 10.1136/lupus-2023-000910.

Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 2021;385:567-9. doi: 10.1056/NEJMc2107725.

Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine 2022;28:2124-32. doi: 10.1038/s41591-022-02017-5.

Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant 2021;36:1474-83. doi: 10.1093/ndt/gfaa117.

Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. Phase ii randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 2021;73:121-31. doi:10.1002/art.41466.

Shipa M, Ribeiro LS, Nguyen D, Embleton-Thirsk A, Parvaz M, Isenberg D, et al. OP0237 distinct immune networks stratify organ involvement and response to B cell targeted therapies in systemic lupus erythematosus. Ann Rheum Dis 2022;81:156-7. doi: 10.1136/annrheumdis-2022-eular.183.

Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70: 2029-36. doi: 10.1136/ard.2011.150326.

Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022;81:951-61. doi: 10.1136/annrheumdis-2021-221425.

Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, et al. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Arthritis Res Ther 2020;22:102. doi: 10.1186/s13075-020-02177-0.

DOI: http://dx.doi.org/10.31584/jhsmr.20241125

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.